Key Events This Week
30 Mar: Stock hits 52-week low of Rs.1,519.35
1 Apr: Opens with a 6.28% gap up, closing at Rs.1,573.70 (+4.10%)
2 Apr: Slight pullback to Rs.1,567.85 (-0.37%)
3 Apr: Week closes at Rs.1,567.85, up 0.68% for the week
Apr 09
BSE+NSE Vol: 51.81 k

Caplin Point Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 25 Nov 2025. However, the analysis and financial metrics presented here reflect the stock's current position as of 08 April 2026, providing investors with an up-to-date view of its fundamentals, valuation, financial trends, and technical outlook.
Read full news article
30 Mar: Stock hits 52-week low of Rs.1,519.35
1 Apr: Opens with a 6.28% gap up, closing at Rs.1,573.70 (+4.10%)
2 Apr: Slight pullback to Rs.1,567.85 (-0.37%)
3 Apr: Week closes at Rs.1,567.85, up 0.68% for the week
Recent Price Movement and Market Context
Caplin Point Laboratories has been under pressure over the past week, with the stock falling 3.60%, significantly underperforming the Sensex, which declined by only 1.03% in the same period. Over the last month, the stock's decline of 10.27% closely mirrors the Sensex's 10.33% drop, indicating sector-wide challenges. However, year-to-date, the stock has fallen 18.37%, outpacing the Sensex's 15.57% decline, and over the last year, the stock has plunged 24.38%, far exceeding the Sensex's 7.06% loss. This divergence highlights company-specific factors weighing on investor sentiment.
On 30-Mar, the stock hit a new 52-week low of ₹1,502.45, marking a fresh nadir in its trading range. The share price has been declining for two consecu...
Read full news article
A sharp decline over the past two sessions has dragged Caplin Point Laboratories Ltd to a fresh 52-week low of Rs 1519.35, marking a 36.6% drop from its peak of Rs 2396.95 within the last year. This underperformance stands in stark contrast to the broader market, with the Sensex down just 6.34% over the same period.
Read full news article
Caplin Point Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 25 Nov 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 28 March 2026, providing investors with the latest insights into the company’s performance and outlook.
Read full news article
Caplin Point Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 25 Nov 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 17 March 2026, providing investors with an up-to-date view of the company's performance and outlook.
Read full news article
Caplin Point Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 25 Nov 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 06 March 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.
Read full news articleCaplin Point Laboratories Limited has informed the Exchange regarding a press release dated December 03, 2019, titled "CAPLIN STERILES GETS USFDA APPROVAL FOR SODIUM NITROPRUSSIDE INJECTION".
Caplin Point Laboratories Limited has informed the Exchange regarding 'Notice of Postal Ballot'.
Caplin Point Laboratories Limited has informed the Exchange regarding Reappointment of Director of the company.
No Upcoming Board Meetings
Caplin Point Laboratories Ltd has declared 150% dividend, ex-date: 12 Sep 25
Caplin Point Laboratories Ltd has announced 2:10 stock split, ex-date: 19 Oct 16
No Bonus history available
No Rights history available